What's in Eye Center of North Florida's pipeline?

Eye Center of North Florida has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eye Center of North Florida's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eye-center-of-north-florida.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Eye Center of North Florida — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eye Center of North Florida pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Imprimis Less Drops	Imprimis Less Drops	marketed	Compounded ophthalmic anti-inflammatory/lubricant		Ophthalmology
Imprimis Dropless	Imprimis Dropless	marketed	Compounded ophthalmic anti-inflammatory and antimicrobial combination		Ophthalmology

Therapeutic area mix

Ophthalmology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Eye Center of North Florida:

Cite this brief

Drug Landscape (2026). Eye Center of North Florida — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eye-center-of-north-florida. Accessed 2026-05-17.